Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
BACE CRISPR/Cas9 KO Plasmid (h2): sc-401500-KO-2
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BACE CRISPR/Cas9 Knockout (KO) Plasmid (h2) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the BACE genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BACE Antibody (61-3E7): sc-33711
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BACE CRISPR/Cas9 KO Plasmid (h2) | sc-401500-KO-2 | 20 µg | $397.00 |
Overview
BACE1 encodes beta-site amyloid precursor protein cleaving enzyme 1 (BACE), an aspartyl protease that initiates the amyloidogenic processing of APP by generating the N-terminus of Aβ peptides. This activity intersects with endosomal trafficking and lysosomal proteostasis, where acidic compartments support BACE maturation and substrate cleavage. BACE1-dependent processing influences synaptic function and neuronal signaling by modulating levels of APP-derived fragments and other neuronal substrates. Dysregulated BACE1 expression or activity has been associated with Alzheimer’s disease-related molecular pathology and is frequently studied in the context of amyloid pathway biology and neurodegeneration mechanisms.
BACE CRISPR/Cas9 KO Plasmid (h2) is a pool of plasmids designed for targeted disruption of the BACE1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the BACE1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the BACE1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BACE protein expression.
This CRISPR knockout system enables efficient generation of BACE1-deficient cell models for investigation of BACE signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting BACE1 exon(s) critical for BACE function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple BACE1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by BACE CRISPR/Cas9 KO Plasmid (h) and BACE CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the BACE1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by BACE HDR Plasmid (h) and BACE HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by BACE1 homology arms to support homology-directed repair at defined BACE1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.